Drug details

Caelyx (pegylated liposomal doxorubicin hydrochloride injection)

type of Antineoplastics, Anthracycline

Caelyx (pegylated liposomal doxorubicin hydrochloride for injection) is an anthracycline topoisomerase II inhibitor indicated for monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk associated with conventional doxorubicin; advanced ovarian carcinoma in women who have failed standard first-line therapy; AIDS-related Kaposi's sarcoma (KS) in patients with low CD4 counts (less than 200 CD4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease whose disease has progressed despite therapy or who are intolerant to prior systemic combination chemotherapy comprising of at least two of the following agents: a vinca alkaloid, bleomycin and doxorubicin (or another anthracycline). Caelyx is a Canadian brand name for liposomal doxorubicin hydrochloride. A brand name for liposomal doxorubicin hydrochloride in the U.S. is Doxil.

This drug may have the following side effects:

• nausea,
• vomiting,
• swelling,
• rash
• redness,
• fatigue,
• hair loss,
• loss of appetite, and
• numbness, and
• inflammation of the mucus membranes of the nose,
• inflammation of the mouth and lips,

The following drugs are related to Caelyx, either as a replacement or used together:

• Arimidex (anastrozole)
• Femara (letrozole)
• Gemzar (gemcitabine hcl)
• Kisqali FeMara Co-Pack (ribociclib and letrozole tablets)
• Lynparza (olaparib capsules for oral administration)
• Nolvadex (tamoxifen citrate)
• Soltamox (tamoxifen citrate)